Author

Carla Maria Boquimpani

Observed names: Boquimpani, C., C Boquimpani, C. Boquimpani, C.M. Boquimpani, Carla Boquimpani, Carla M Boquimpani, Carla M. Boquimpani

Institution: Hemorio

Observed institutions: Universidade Federal do Rio de Janeiro, Hemorio

ORCID: 0000-0001-7396-2495

Observed ORCID: 0000-0001-7396-2495

OpenAlex ID: A5046495135

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

2021 · Hagop M. Kantarjian, Timothy P. Hughes, et al. · Leukemia · 351

PDF

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

2021 · Delphine Réa, Michael J. Mauro, et al. · Blood · 344

PDF

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

2023 · Andreas Hochhaus, Delphine Réa, et al. · Leukemia · 148

PDF

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

2018 · François-Xavier Mahon, Carla Boquimpani, et al. · Annals of Internal Medicine · 134

Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel

2021 · Carolina Pavlovsky, Virginia Abello Polo, et al. · Blood Advances · 40

Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients—An analysis from the Brazilian Hodgkin Lymphoma Registry

2017 · Irene Biasoli, Nelson Castro, et al. · International Journal of Cancer · 31

PDF

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

2019 · Timothy P. Hughes, Giuseppe Saglio, et al. · Blood · 27

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

2020 · Andreas Hochhaus, Carla Boquimpani, et al. · Blood · 26

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors

2023 · Ehab Atallah, Michael J. Mauro, et al. · Journal of Cancer Research and Clinical Oncology · 24

PDF

Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry

2017 · Irene Biasoli, Nelson Castro, et al. · Hematological Oncology · 24

2023 · Delphine Réa, Carla Boquimpani, et al. · Leukemia · 21

PDF

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

2016 · Timothy P. Hughes, Carla Maria Boquimpani, et al. · Blood · 21

Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR)

2014 · Carla Maria Boquimpani, Tomasz Szczudlo, et al. · Blood · 21

BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival

2015 · Katia Borgia Barbosa Pagnano, Israel Bendit, et al. · Cancer Investigation · 19

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

2021 · Michael J. Mauro, Yosuke Minami, et al. · Blood · 18

Vox Sanguinis International Forum on transfusion services' response to COVID‐19: Summary

2020 · Mark H. Yazer, Bryon Jackson, et al. · Vox Sanguinis · 17

PDF

Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study

2021 · Pedro Kurtz, Cassia Righy, et al. · Frontiers in Medicine · 16

PDF

Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.

2016 · Timothy P Hughes, Carla Boquimpani, et al. · Journal of Clinical Oncology · 13

Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib

2014 · Carla Boquimpani, Rony Schaffel, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 13

Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL

2025 · Michael J. Mauro, Yosuke Minami, et al. · Blood Advances · 12

PDF

Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

2021 · Hagop M. Kantarjian, Timothy P. Hughes, et al. · Leukemia · 11

PDF

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

2016 · François-Xavier Mahon, Carla Maria Boquimpani, et al. · Blood · 11

Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.

2022 · Delphine Rea, Michael J. Mauro, et al. · Journal of Clinical Oncology · 10

ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

2019 · Timothy P. Hughes, Carla Boquimpani, et al. · Journal of Clinical Oncology · 9

P668: Chronic Myeloid Leukemia Survey on Unmet Needs (cml Sun): Balancing Tolerability and Efficacy Goals of Patients and Physicians Through Shared Treatment Decision-making

2023 · Fabian Lang, Zack Pemberton-Whiteley, et al. · HemaSphere · 8

Works count: 84

Citation count: 1,481

H-index: 16

I10-index: 23